The Centers for Disease Control and Prevention states that there are an estimated 11 to 21 million cases of typhoid fever annually. It is also reported that typhoid and paratyphoid fever are responsible for 135,000 to 230,000 deaths worldwide each year. This data highlights the need for pipeline expansion to eliminate typhoid as a public health threat. Further, the rise of multidrug-resistant Salmonella Typhi is stimulating the development of novel antibiotics and other alternative treatments.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to typhoid fever are covered.
There is an increased interest towards the development of vaccines that provide longer-lasting immunity and are suitable for all age groups. Further, growing research into combination vaccines and the rise in mass vaccination campaigns are expected to positively impact the pipeline landscape for typhoid fever.
The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for typhoid fever.
This product will be delivered within 3-5 business days.
Report Coverage
The Typhoid Fever Drug Pipeline Report by the publisher gives comprehensive insights into typhoid fever drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for typhoid fever. The report includes the analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from typhoid fever.The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to typhoid fever are covered.
Typhoid Fever Drug Pipeline Outlook
Typhoid fever is caused by the bacterium Salmonella typhi and is spread through contaminated food or water. The bacterial infection can be life-threatening if left untreated. Symptoms include high fever, headache, fatigue, and abdominal pain, among others. Typhoid fever is typically treated with antibiotics. However, antimicrobial resistance is common and severe cases may require hospitalization. Typhoid fever is common in regions such as Africa, South-East Asia, Eastern Mediterranean, and Western Pacific regions.There is an increased interest towards the development of vaccines that provide longer-lasting immunity and are suitable for all age groups. Further, growing research into combination vaccines and the rise in mass vaccination campaigns are expected to positively impact the pipeline landscape for typhoid fever.
Typhoid Fever - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of typhoid fever drugs based on several segmentations including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Vaccines
- Small Molecule Antibiotics
- Monoclonal Antibodies
- Peptide-based Therapeutics
By Route of Administration
- Oral
- Parenteral
- Others
Typhoid Fever - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase IV covers a major share of the total clinical trials for typhoid fever.Typhoid Fever - Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under typhoid fever pipeline analysis include vaccines, small molecule antibiotics, monoclonal antibodies, and peptide-based therapeutics. The treatment for typhoid fever depends on the patient’s overall health and antibiotic resistance in the region. Antibiotics are commonly prescribed to the patient to kill the Salmonella Typhi bacteria. Common antibiotics include ciprofloxacin, azithromycin, and ceftriaxone.The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for typhoid fever.
Typhoid Fever Clinical Trials Assessment - Competitive Dynamics
The report for the typhoid fever drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in typhoid fever clinical trials:- PT Bio Farma
- Avant Immunotherapeutics
- GlaxoSmithKline
- EuBiologics Co., Ltd
- Matrivax Research and Development Corporation
- Prokarium Ltd
- Novartis
- Bavarian Nordic
- Emergent BioSolutions
- Sanofi Pasteur, a Sanofi Company
- Janssen Pharmaceutica N.V.
Typhoid Fever - Pipeline Drugs Profile
Leading drugs currently in pipeline are as follows:
Drug: Azithromycin, Drug: Cefixime
The randomized controlled clinical study was designed to compare and evaluate the efficacy of a combination of azithromycin and cefixime against azithromycin alone in outpatients with suspected or confirmed uncomplicated typhoid fever in South Asia. This Phase IV interventional trial has enrolled around 1500 participants.Biological: Vi-DT Typhoid Conjugate Vaccine
Sponsored by PT Bio Farma, this Phase II/III trial aims to assess how long the Vi-DT typhoid vaccine remains effective by measuring antibody titer in individuals 2, 3, 4, and 5 years after vaccination. The study has enrolled around 188 Indonesian adults, adolescents, children, and infants.Biological: Typbar-TCV
The objective of this clinical trial is to investigate the efficacy of a single dose of the Typbar-TCV® vaccine against blood culture-confirmed typhoid fever. The vaccine was administered to children aged 9 months to under 16 years during a mass vaccination campaign in Kisantu, Democratic Republic of Congo (DRC). Sponsored by the International Vaccine Institute, the study is in Phase IV clinical development and has an estimated 48,000 participants.Reasons To Buy This Report
The Typhoid Fever Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for typhoid fever. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the typhoid fever pipeline insights.Key Questions Answered in the Typhoid Fever - Pipeline Assessment Report
- What is the current landscape of typhoid fever pipeline drugs?
- How many companies are developing typhoid fever drugs?
- How many phase III and phase IV drugs are currently present in typhoid fever pipeline drugs?
- Which companies/institutions are leading the typhoid fever drug development?
- What is the efficacy and safety profile of typhoid fever pipeline drugs?
- What are the opportunities and challenges present in the typhoid fever drug pipeline landscape?
- Which company is conducting major trials for typhoid fever drugs?
- What geographies are covered for typhoid fever clinical trials?
- What are emerging trends in typhoid fever clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Typhoid Fever Pipeline
4 Patient Profile: Typhoid Fever Pipeline
5 Typhoid Fever Pipeline: Epidemiology Snapshot
6 Typhoid Fever Pipeline: Market Dynamics
7 Typhoid Fever Pipeline: Key Facts Covered
8 Typhoid Fever Pipeline, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Typhoid Fever Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Typhoid Fever Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Typhoid Fever Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Typhoid Fever Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Typhoid Fever, Key Drug Pipeline Companies
